Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Slide Insurance Q4 2025 Earnings Call - Record Q4 as Citizens depopulation and reserve tailwinds fuel 57% GWP growth and $170M net income
Slide closed 2025 with blowout results, driven by opportunistic Citizens depopulation, strong voluntary sales and favorable prior-year reserve development. Q4 gross written premium jumped 57% to $618....
- Q4 2025 gross premiums written of $618.5 million, up 57% year-over-year, driven by Citizens depopulation and higher voluntary sales.
- Slide assumed ~152,000 policies from Citizens in the quarter, bringing policies in force to ~493,500, a 44% YoY increase.
- Net income for the quarter was $170.4 million, more than double the prior year quarter's $75.1 million; diluted EPS $1.23.
- +13 more takeaways
Lineage Fourth Quarter 2025 Earnings Call - Seasonality Returns; Guidance AFFO $2.75-$3.00, $50M Cost Cuts and $150M Development EBITDA
Lineage reported Q4 2025 results that were roughly in line with expectations, with total revenue flat year-over-year and adjusted EBITDA down 2% to $327 million. Physical occupancy showed a meaningful...
- Q4 revenue was flat year-over-year, adjusted EBITDA declined 2% to $327 million, and Q4 AFFO per share was flat at $0.83.
- Full-year 2025 adjusted EBITDA fell 2.3% to about $1.3 billion, while full-year AFFO per share rose 2.4% to $3.37, aided by better tax planning and lower maintenance capex.
- Physical same-store occupancy improved sequentially by 400 basis points to 79.3%, signaling a return to more normal seasonality and management believes inventory destocking is largely behind them.
- +12 more takeaways
Luxfer Holdings PLC Q4 2025 Earnings Call - Elektron drove earnings, guidance cautious as restructuring and timing headwinds push benefits into late 2026
Luxfer closed 2025 with modest top-line growth and cleaner earnings, led squarely by Elektron. Adjusted sales rose to $371.2 million, adjusted EBITDA to $51.9 million and adjusted EPS to $1.11, while ...
- Company posted adjusted full-year sales of $371.2 million, up 2.5% year-over-year, with adjusted EBITDA of $51.9 million, up 4.2%.
- Adjusted EPS rose 12.1% to $1.11 for 2025, reflecting operating leverage and portfolio mix shifts toward higher-margin products.
- Elektron was the clear performance engine: full-year sales of $196.4 million, up 11.6%, and adjusted EBITDA of $36.9 million, up 16%, with margins expanding toward the 20% target (full-year Elektron margin 18.8%, Q4 margin 19.6%).
- +11 more takeaways
Hippo Fourth Quarter 2025 Earnings Call - Diversified commercial growth and underwriting discipline drove profitable scale
Hippo closed 2025 with clear evidence that a shift from growth-at-all-costs to disciplined underwriting is working. The company reported over $1.1 billion of gross written premium, a 24% increase year...
- Gross Written Premium reached over $1.1 billion in 2025, up 24% year-over-year, with Q4 GWP of $288 million, up 40% YoY.
- Net Written Premium was $422 million for the year, up 13% versus 2024.
- Full-year Net Income attributable to Hippo was $58 million, or $2.22 per diluted share, a $98 million improvement year-over-year.
- +16 more takeaways
Immunocore Q4 & Full Year 2025 Earnings Call - KIMMTRAK $400M, Phase 3 Readouts Point to a Make-or-Break 2H26
Immunocore closed 2025 on commercial strength, with KIMMTRAK delivering $400 million in net revenue, up 29% year-on-year, broader global rollout and real-world duration of therapy now 14 months. Manag...
- KIMMTRAK net revenue reached $400 million in 2025, a 29% increase versus 2024.
- KIMMTRAK is approved in 39 countries and launched in 30 markets, with real-world mean duration of therapy at 14 months.
- Real-world evidence presented at ESMO IO from 150 patients showed a median overall survival of 28 months; company will publish additional U.S. RWE and 5-year registrational OS data in 2026.
- +13 more takeaways
Geron Corporation Q4 2025 Earnings Call - RYTELO set to scale in 2026 with $220M-$240M guidance targeting ~8,000 second-line lower-risk MDS patients
Geron closed 2025 with a full commercial year behind RYTELO and is explicitly repositioning as a U.S.-focused hematology commercial story in 2026. Q4 net revenue was $48 million and full-year RYTELO s...
- RYTELO net revenue: Q4 2025 was $48 million; full-year 2025 RYTELO net revenue totaled $184 million (vs $76M in 2024).
- 2026 guidance: RYTELO net revenue of $220M to $240M; total operating expenses guided to $230M to $240M, implying roughly $20M YoY reduction at the midpoint. Management expects a back-half-weighted growth cadence in 2026.
- Commercial focus: Geron is prioritizing second-line, lower-risk MDS patients in the U.S., estimating an addressable population of approximately 8,000 patients. Second-line is the primary growth lever.
- +11 more takeaways
Amarin Corporation Q4 2025 Earnings Call - Recordati partnership and restructuring put company on cash-flow positive path
Amarin used 2025 to pivot from a standalone commercial model to a partnered international strategy and to slash costs, and the early results are tangible. The recordati licensing deal delivered $25 mi...
- Q4 2025 total net revenue was $49.2 million, down from $62.3 million year-over-year, driven by U.S. pricing declines and prior-year stocking in Rest of World markets.
- U.S. net sales declined 7% in Q4 due to lower net selling price; management expects the bulk of annual U.S. volume declines to occur in Q1 because of payer annual reset dynamics.
- Amarin says VASCEPA retains market leadership among all icosapent ethyl products in the U.S. five years after the first generic entry, and major managed care exclusives were maintained through 2025.
- +14 more takeaways
Dole plc Q4 and Full Year 2025 Earnings Call - $395M Adjusted EBITDA, Targeting at least $400M in 2026 Amid Fresh Fruit Cost Headwinds
Dole closed 2025 with resilient operating results and a clear pivot toward a simpler, more capital flexible company. Adjusted EBITDA for the year was $395 million, revenue rose to $9.2 billion, and ma...
- Adjusted EBITDA for full year 2025 was $395 million, coming in ahead of the company's latest guidance.
- Management is targeting at least $400 million of Adjusted EBITDA for 2026, with a caveat: early-year supply and cost headwinds may weight profits toward the back half of the year.
- Revenue for the year rose to $9.2 billion, an 8.2% increase year over year; Q4 revenue was $2.4 billion, up 9.2% reported and 5.7% like-for-like.
- +12 more takeaways
Diageo F26 Interim Earnings Call - Dividend cut to fund competitiveness and Guinness capacity
Diageo described the F26 interim results as mixed: strength in Latin America, Europe and Africa offset by notable weakness in Chinese white spirits and North America. Management reconfirmed near-term ...
- Results described as mixed: encouraging performance in Latin America, Europe and Africa, offset by weakness in Chinese white spirits and North America.
- Board revised dividend policy to a 30%–50% payout range to free up cash for reinvestment and faster balance sheet repair.
- Management reaffirmed commitment to generating ~3 billion of cash this year (figure referenced in the call).
- +12 more takeaways
HSBC Holdings PLC FY2025 Earnings Call - Hang Seng Privatization Unlocks Growth, Targets 17%+ RoTE and 5% Revenue by 2028
HSBC closed 2025 with a strong performance and a clear strategic pivot: deliver disciplined simplification, double down on customer-led growth, and redeploy capital into high-return markets. Results: ...
- FY2025 group revenues rose 5% on a constant currency basis, with profit before tax up 7% to a record $36.6 billion, excluding notable items.
- Return on tangible equity reached 17.2% for 2025, and management targets RoTE of 17% or better in each year from 2026 to 2028, excluding notable items.
- HSBC completed the $13.7 billion privatization of Hang Seng Bank on 26 January 2026, removing a $3.8 billion minority capital inefficiency and increasing balance sheet flexibility.
- +12 more takeaways